Baseline OCT Findings in Phase 3 RESCUE and REVERSE Trials

Update Item Information
Identifier 20180306_nanos_posters_170
Title Baseline OCT Findings in Phase 3 RESCUE and REVERSE Trials
Creator Robert Sergott, Barrett Katz
Subject Genetic Disease, Optic neuropathy, Diagnostic Tests (ERG, VER, OCT, HRT, mfERG, etc) Eyelid & adnexal disease
Description rAAV2/2-ND4 is an investigational gene therapy facilitating allotopic transgene expression. We report baseline spectral domain OCT of the RNFL and GCL in two Phase 3 trials.
Date 2018-03
Language eng
Format application/pdf
Source 2018 North American Neuro-Ophthalmology Society Annual Meeting
Relation is Part of NANOS 2018: Poster Presentations
Collection Neuro-ophthalmology Virtual Education Library: NOVEL http://NOVEL.utah.edu
Publisher Spencer S. Eccles Health Sciences Library, University of Utah
Holding Institution North American Neuro-Ophthalmology Association. NANOS Executive Office 5841 Cedar Lake Road, Suite 204, Minneapolis, MN 55416
Rights Management Copyright 2018. For further information regarding the rights to this collection, please visit: https://NOVEL.utah.edu/about/copyright
ARK ark:/87278/s61013gq
Context URL The NANOS Annual Meeting Neuro-Ophthalmology Collection: https://novel.utah.edu/collection/NAM/toc/
Contributor Primary Robert Sergott
Contributor Secondary Barrett Katz
Setname ehsl_novel_nam
ID 1309590
Reference URL https://collections.lib.utah.edu/ark:/87278/s61013gq
Back to Search Results